Press Release
Dear Sir / Madam, We wish to inform that the USFDA inspected our formulations manufacturing facility at Baddi from 20th February 2017 to 1st March 2017. At the end of the inspection, there were 3 observations given under form 483. All these three observations are related to Pre-Approval Inspection (PAI) for a specific product filed. This product is yet to be manufactured or marketed in the US. The company is already in the process of responding...02-03-2017